Prolysis "developing tomorrow's antibiotics today"

Prolysis is an antibacterial drug discovery and development company based in Oxford, UK. We are focused on creating new antibacterial drugs that are urgently needed to treat hospital-acquired and community-associated infections.

News

• Prolysis to present at a Gordon Research Conference in Lucca, Italy
  5th February 2008
• Prolysis receives a £3.48 million Seeding Drug Discovery award from the Wellcome Trust
  15th January 2007
• Prolysis publishes a research paper describing a novel antibacterial target
  12th January 2007
• Prolysis invited to present at Superbugs & Superdrugs conference in London
  24th April 2006
• Professor Jeff Errington FRS completes the relocation of his research team
  18th April 2006